Drug intelligence / Profile preview

liposomal latanoprost

Development stage: Phase 2
Lead developer: Peregrine Ophthalmic
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Subconjunctival

Overview

Liposomal latanoprost is a sustained-release formulation of latanoprost, a prostaglandin F2α analog used to treat glaucoma and ocular hypertension. The drug is encapsulated in liposomes (phospholipid vesicles) that allow for extended release over time. This formulation significantly increases ocular bioavailability and extends the duration of IOP-lowering effects compared to conventional latanoprost eye drops. When administered via subconjunctival injection, it can maintain therapeutic effects for up to 50 days, compared to daily administration required for traditional eye drops.

Brand names: LIPOLAT
Other names: latanoprost extended releaselatanoprost liposomal

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on liposomal latanoprost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liposomal latanoprost.

Explore the full profile